Clinical trials: HSV-1
Melanoma Stage III, Melanoma Stage IV
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
The purpose of this study is to determine if TBI-1401(HF10) in combination with ipilimumab is effective in Japanese patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.
- Trial name
- NCT03153085
- Testing
- TBI-1401(HF10), Ipilimumab
- Where
- 12 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Takara Bio Inc.
Refractory Head and Neck Cancer, Squamous Cell Carcinoma, Skin
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
The purpose of this study is to determine whether HF10 is safe and effective in the treatment of head and neck cancer or solid tumors with cutaneous and/or superficial lesions.
- Conditions
- Refractory Head and Neck Cancer, Squamous Cell Carcinoma, Skin, Carcinoma of the Breast, Malignant Melanoma
- Trial name
- NCT01017185
- Testing
- HF10
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Takara Bio Inc.
Metastatic Uveal Melanoma
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been…
- Trial name
- NCT06581406
- Testing
- RP2, Ipilimumab, Nivolumab
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 280 people
- Sponsor
- Replimune, Inc.
Herpes Labialis
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection
This is a phase II, double-blind, randomised, controlled, multicentre trial of topical HDIT101 versus placebo. HSV-1-positive patients with at least 6 orolabial herpes lesions in the last 12 months can be included.
- Trial name
- MATCH-1 (NCT04539483)
- Testing
- HDIT101 (blinded therapy), Photo documentation of orolabial herpes lesions, Completion of questionnaires (patient-reported outcomes)
- Where
- 5 sites in Germany
- Volunteers
- 761 people
- Sponsor
- Heidelberg ImmunoTherapeutics GmbH
Solid Tumor, Glioblastoma
A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma
This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine the safety and tolerability of a single intratumoral (IT) injection of C5252 in patients with recurrent or progressive glioblastoma…
- Conditions
- Solid Tumor, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain
- Trial name
- NCT05095441
- Testing
- C5252
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- ImmVira Pharma Co. Ltd
Malignant Melanoma
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
The purpose of this study is to determine if HF10 in combination with ipilimumab is effective in patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.
- Trial name
- NCT02272855
- Testing
- HF10 plus Ipilimumab
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Takara Bio Inc.
Herpes Simplex Infections
Evaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic Subjects
This clinical performance study is being conducted to evaluate the performance of the Aptima Herpes Simplex Viruses 1 \& 2 assay for detection of herpes simplex virus (HSV) type 1 (HSV-1) and HSV type 2 (HSV-2) in swab samples…
- Trial name
- NCT02270099
- Where
- 22 sites in United States
- Volunteers
- 839 people
- Sponsor
- Hologic, Inc.
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.
The purpose of this study is to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer.
- Trial name
- NCT03252808
- Testing
- TBI-1401(HF10), Gemcitabine, Nab-paclitaxel
- Where
- 8 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Takara Bio Inc.
Herpes
A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&2 Assay in Symptomatic Patients
The ARIES HSV 1\&2 Assay is a PCR based test for the direct detection and typing of herpes simplex virus (HSV 1 \& 2) DNA. The objective is to establish the diagnostic accuracy of ARIES HSV-1\&2 Assay.
- Trial name
- NCT02092233
- Where
- 3 sites in United States
- Volunteers
- 1,963 people
- Sponsor
- Luminex Corporation
Viral Keratitis, Blindness Eye
Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of BD111 CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy administered via corneal injection in participants with…
- Conditions
- Viral Keratitis, Blindness Eye, Herpes Simplex Virus Infection, Cornea
- Trial name
- NCT04560790
- Testing
- BD111 Adult single group Dose
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Malignant Glioma
G207 Followed by Radiation Therapy in Malignant Glioma
This is an open-label, single site study to evaluate the safety and tolerability of intratumoral administration of G207 followed by treatment with radiation therapy in patients with recurrent/progressive malignant glioma.
- Trial name
- NCT00157703
- Testing
- G207
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- MediGene
Dystrophic Epidermolysis Bullosa
A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients
This study was conducted to assess the safety and efficacy of topical Beremagene Geperpavec (KB103, HSV1-COL7) on DEB patients.
- Trial name
- GEM-1 (NCT03536143)
- Testing
- Topical beremagene geperpavec
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Krystal Biotech, Inc.
HSV
Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects with Treatment Resistant Herpes Simplex Virus Type 1 or 2
AiCuris Anti-infective Cures AG (AiCuris) is developing pritelivir for the oral treatment of acyclovir-resistant (ACV-R) mucocutaneous herpes simplex virus (HSV) infections in immunocompromised subjects.
- Trial name
- NCT05844436
- Testing
- Pritelivir
- Sponsor
- AiCuris Anti-infective Cures AG
Herpes Simplex Virus Type I Stromal Keratitis
A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis
This study aims to compare the clinical efficacy and safety of BD111 injection in combination with standard therapy vs. standard therapy in herpes simplex virus type I stromal keratitis (HSK), providing preliminary confirmation…
- Trial name
- NCT06474442
- Testing
- BD111 Injection (investigational new drug), Triple-drugs therapy of HSV-1 stromal keratitis
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Head and Neck Cancer, Esophageal Cancer
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
9 participants are expected to be enrolled for this open，single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory head and neck cancer.
- Conditions
- Head and Neck Cancer, Esophageal Cancer, Otorhinolaryngologic Neoplasms, Ear Cancer
- Trial name
- NCT05830240
- Testing
- Recombinant oncolytic herpes simplex virus type 1 (R130)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Yunying Medical Technology
Lung Cancer, Bronchial Cancer
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
24 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory advanced solid tumors.
- Conditions
- Lung Cancer, Bronchial Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT05886075
- Testing
- Recombinant oncolytic herpes simplex virus type 1 (R130)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Yunying Medical Technology
Osteosarcoma, Sarcoma
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory bone and soft tissue…
- Conditions
- Osteosarcoma, Sarcoma, Sarcoma,Soft Tissue, Bone Tumor
- Trial name
- NCT05851456
- Testing
- Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Yunying Medical Technology
Autosomal Recessive Ichthyosis
Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)
KB105-02 is an intrasubject randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of KB105 in children and adults with autosomal recessive congenital ichthyosis (ARCI).
- Trial name
- NCT05735158
- Testing
- KB105
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Krystal Biotech, Inc.
Osteosarcoma, Sarcoma
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
9 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced bone and soft tissue tumors.
- Conditions
- Osteosarcoma, Sarcoma, Soft Tissue Sarcoma, Bone Tumor
- Trial name
- NCT06171282
- Testing
- Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Yunying Medical Technology
TGM-1 Related Autosomal Recessive Congenital Ichthyosis
Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)
This study is an intra-patient comparison of KB105 and placebo-administered Target Areas. The primary objectives of this study are to evaluate safety and Investigator Global Assessment (IGA) scale improvement of topically…
- Trial name
- NCT04047732
- Testing
- KB105
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Krystal Biotech, Inc.